Health Care

Insightful insider trading at Artivion: VP Amy sells to cover tax, buys restricted shares, and CEO, CFO, and other execs’ trades show balanced activity – a sign of confidence amid price dips.

Avantor insider moves: EVP Claudius sells 2,376 shares amid stock volatility – what it means for investor confidence and future prospects.

CEO Nello Mainolfi’s 10b5‑1 trades show deep confidence in Kymera Therapeutics—buying at lows, selling as the stock climbs—offering investors a bullish insider insight into its protein‑degradation pipeline.

Insider buying and RSU sales by Supernus CFO signal cautious optimism ahead of potential pipeline milestones, hinting at a strategic liquidity move.

Arvinas insider sales are routine, not a red‑flag. Loomis’s tax‑sale shows standard RSU settlement; the company’s biotech pipeline remains a key focus.

Danaher insider sale: Couchara Georgeann sells 101 shares at $209, amid broader executive activity and upcoming acquisitions—what this means for investors.

Insider selling spurs analysis of Cullinan Therapeutics’ stock trend and potential liquidity strategy—what it means for investors.

CEO Brenton Saunders sells 65k Bausch + Lomb shares below market—yet insider buys suggest confidence, not distress, in the eye‑care firm’s future.

Nehall’s recent buy‑sell at Supernus signals cautious optimism—balanced insider confidence that could hint at a short‑term rally.

PROCEPT BioRobotics insider buying signals confidence amid volatility—Alaleh’s recent PSU‑triggered purchase may hint at a future rebound for the struggling stock.